Hemab Therapeutics presented promising clinical data for HMB-002, a subcutaneous treatment for Von Willebrand disease (VWD), showing dose-dependent increases in Von Willebrand Factor and Factor VIII, with potential for monthly dosing and a favorable safety profile. Additionally, Hemab introduced HMB-003, a non-hormonal antifibrinolytic designed to reduce heavy menstrual bleeding by inhibiting plasmin, with extended activity supporting cycle-matched dosing. These developments could improve treatment options for bleeding disorders that currently lack effective preventive therapies. Hemab plans further clinical trials to confirm efficacy and safety.
The Global X Russell 2000 Covered Call ETF (RYLD) provides a high monthly yield of 11.9% and achieved a 20.5% total return over the past year. However, its strategy involving at-the-money options causes structural net asset value (NAV) erosion and ca...
A Cambridge study found Ethereum's annual energy consumption at 7.87 gigawatt-hours, making it the second-least energy-intensive proof-of-stake (PoS) blockchain when adjusted for market value. This marks a significant improvement from its previous pr...
The IBIT Bitcoin ETF, managed by BlackRock, recorded a $292 million net inflow last week, reversing eight consecutive weeks of outflows. This inflow reflects renewed institutional interest in Bitcoin, which currently trades near $70,000. Market confi...
After a 72% price drop, XRP has reached extreme bearish sentiment, with heavy short interest and negative funding rates on Binance. Analysts like Crypto Patel see this as a contrarian buy signal, noting past rebounds of over 100% after similar condit...
Frontline plc, a leading crude oil tanker company, is rated a Strong Buy with a $52 price target, suggesting a 42% potential gain from current prices. The company has secured 82% of its VLCC tanker days at a high rate of $181,700 per day for Q2, supp...
